Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
ionizing radiation
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "ionizing radiation" in MCE Product Catalog:
Cat. No.: HY-112418
CAS No.: 546102-60-7
CDK4/6-IN-18 (Example 2BrIC) is a selective CDK4/6 inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .
Cat. No.: HY-178503
dA-NHbenzylSCF 3 is a radiosensitizer. dA-NHbenzylSCF 3 has low toxicity to cancer cells and normal cells, but can significantly enhance cancer cell death in the presence of ionizing radiation (IR). dA-NHbenzylSCF 3 promotes cell apoptosis by capturing electrons and inducing DNA double strand breaks (DSBs). dA-NHbenzylSCF 3 is often used in the research of cancer, such as prostate cancer and breast cancer .
Cat. No.: HY-N0153A
CAS No.: 132203-74-8
Synonyms: Naringoside hydrate
Target:
Research Areas:
Niacinamide ascorbate is a vitamin complex that combines niacinamide (vitamin B3) and ascorbic acid (vitamin C). Niacinamide ascorbate reduces the risk of radiation-induced acute leukemia, breast cancer, thyroid cancer, and other somatic and genetic mutations following exposure to ionizing radiation doses .
Cat. No.: HY-113266R
CAS No.: 40225-14-7
Cat. No.: HY-12364C
CAS No.: 1234694-20-2
Synonyms: (+)-C75
Research Areas:
(+)-trans-C75 ((+)-C75) is an enantiomer of C75 (HY-12364) (a fatty acid synthase inhibitor). (+)-trans-C75 is less potent than the racemic mixture or the (-) enantiomer in enhancing the cancer-killing ability of ionizing radiation. (+)-trans-C75 inhibits CPT1 and is an anorectic agent .
Cat. No.: HY-113266S
CAS No.: 2847775-89-5
Synonyms: C5:0 L-carnitine-d9
Research Areas:
Valerylcarnitine-d9 (C5:0 L-carnitine-d9) is the deuterium labeled Valerylcarnitine (HY-113266). Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
Cat. No.: HY-N0232R
CAS No.: 18642-23-4
Cat. No.: HY-W013973R
CAS No.: 92-94-4
Cat. No.: HY-P1698B
Synonyms: AB-103 TFA
Research Areas:
Cat. No.: HY-L178
3,066 compounds
Radiation sickness is a general term for various types and degrees of damage (or disease) occurring in the human body after exposure to ionizing radiation. Although small amounts of ionizing radiation can also cause the body to produce free radicals and ROS, causing oxidative stress, resulting in DNA damage and chromosomal aberration. Radioprotector are compounds with radiation protection that can be used to prevent/protect non-tumor cells from the harmful effects of radiation. Radioprotective compounds can prevent the damage of radioactive substances to the human body and reduce the clinical symptoms of various radioactive diseases. In addition, radioprotectors can protect normal cells from damage during radiation therapy. The ideal anti-radiation drug should not affect the sensitivity of tumor cells to radiation therapy while protecting normal cells.
MCE designs a unique collection of 3,066 radioprotectors. Radioprotector Library is an effective tool for acute Radiation Syndrome, drug combination research with radiation drugs.
Cat. No.: HY-W013973S
CAS No.: 1718-51-0
Cat. No.: HY-P1698A
CAS No.: 1943755-99-4
Synonyms: AB-103 sodium
Research Areas:
Reltecimod sodium (AB-103 sodium) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod sodium has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod sodium modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod sodium can be used to research necrotizing soft-tissue infections (NSTIs) .
Cat. No.: HY-183334
CAS No.: 3115524-78-9
Research Areas:
TDP1-IN-5 is a tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 of 2.2 μM. By targeting TDP1 both intracellularly and extracellularly, TDP1-IN-5 inhibits the NHEJ repair pathway, arrests the cell cycle at the G2/M phase, upregulates PIG3 to enhance ROS, and ultimately significantly potentiates ionizing radiation (IR)-induced DNA damage and apoptosis. TDP1-IN-5 can be used in the research of colorectal cancer .
Cat. No.: HY-180573
Target:
Research Areas:
ART5537 is a selective EXO1 inhibitor with a IC50 of 3.4 nM and a Kd of 6.8 nM. ART5537 exerts cellular homologous recombination (HR) inhibition with EC50 of 7.2 nM in HAP1 parental cells. ART5537 shows >200-fold selectivity over a panel of the wider nuclease superfamily. ART5537 exerts biological effects that are exclusively driven by EXO1 inhibition. ART5537 demonstrates sensitization to ionizing radiation and synergy with Olaparib (HY-10162). ART5537 can be used for research in breast cancer and colorectal adenocarcinoma .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
